26 July 2018 - NICE has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund for a subgroup of people with relapsed or refractory classical Hodgkin's lymphoma.

The Institute noted that there are limited treatment options for people who have not responded to, or only temporarily respond to, brentuximab vedotin and cannot have stem cell transplant.

While the evidence shows that Keytruda (pembrolizumab) increased progression-free survival and response rates, long-term evidence of clinical effectiveness remains uncertain, it said.

Read Pharma Times article